From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
|Articles|December 3, 2018
Monday Pharmaceutical Mystery: December 3
Author(s)Gunda Siska, PharmD
Can you solve the pharmaceutical mystery? Each week, a new case study is presented.
Advertisement
A gentleman aged 70 years comes into the pharmacy with his daughter. She is assisting him as he walks. His is also having difficulty speaking, and his hand is shaky as he hands you the refill information. He requests an early refill of his pain medication, gabapentin, which the insurance declines. You remember seeing him 2 weeks ago, and he was completely independent.
Mystery: What has happened to him? He seems to have had a stroke or developed some sort of altered mental status.
Solution: He is having adverse effects from taking too much gabapentin.
Advertisement
Related to this article
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Pharmacists can strengthen opioid safety through individualized counseling, overdose prevention, and coordinated follow-up that keeps patients involved in treatment decisions.
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
2
Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines
3
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
4
Glucose Monitoring: Timing Makes Every Reading Count
5